Skip to main content

PepGen Inc.

corporate_fare Company Profile

PepGen Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed PEPG - Latest Insights

PEPG
Apr 28, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
PepGen Details Executive Option Repricing and Significant Potential Dilution in Proxy Filing
Sentiment: Negative
View Wiseek Article
PEPG
Mar 30, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
8
Favorable Safety, Splicing Trends Emerge for PepGen's Lead Drug PGN-EDODM1
Sentiment: Positive
View Wiseek Article
PEPG
Mar 30, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
8
PepGen Reports Favorable Safety and Splicing Trends for PGN-EDODM1 in Lowest Dose DM1 Trial
Sentiment: Positive
View Wiseek Article
PEPG
Mar 04, 2026, 5:02 PM EST
Filing Type: 8-K
Importance Score:
9
FDA Imposes Partial Clinical Hold on PepGen's FREEDOM2 DM1 Trial
Sentiment: Negative
View Wiseek Article
PEPG
Mar 04, 2026, 4:41 PM EST
Source: Reuters
Importance Score:
7
PepGen's Q4 Net Loss Narrows to $18.3M, Cash Runway Extends into 2H 2027
Sentiment: Neutral
View Wiseek Article
PEPG
Mar 04, 2026, 4:28 PM EST
Source: Reuters
Importance Score:
8
FDA Imposes Partial Clinical Hold on Pepgen's Key FREEDOM2 Trial Over Preclinical Concerns
Sentiment: Negative
View Wiseek Article
PEPG
Mar 04, 2026, 4:15 PM EST
Filing Type: 10-K
Importance Score:
9
PepGen Faces Clinical Hold on Lead DM1 Program, Discontinues DMD Program, and Reports Dilutive $107.6M Offering
Sentiment: Negative
View Wiseek Article